Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101

Autor: Daisuke Shimizu, Kazutaka Narui, Masatoshi Mogaki, Akihiko Suto, Tomohiko Ota, Takashi Ishikawa, Naoki Niikura, Yutaka Tokuda, Takeshi Sasaki, Mikiko Tanabe, Akimitsu Yamada, Takashi Chishima, Masaru Kuranami, Yasushi Ichikawa, Yuki Saito, Koichiro Tsugawa, Haruki Ogata, Mari S. Oba, Kumiko Kida, Hitoshi Arioka, Norihiko Sengoku, Shuichi Nawata, Yoshimasa Kosaka, Takako Doi, Itaru Endo, Satoshi Morita, Yasuhiro Suzuki
Rok vydání: 2019
Předmět:
Adult
Oncology
endocrine system
medicine.medical_specialty
Cyclophosphamide
Anthracycline
Phases of clinical research
Breast Neoplasms
Triple Negative Breast Neoplasms
Docetaxel
Kaplan-Meier Estimate
Mastectomy
Segmental
Risk Assessment
Disease-Free Survival
Drug Administration Schedule
Statistics
Nonparametric
03 medical and health sciences
0302 clinical medicine
Breast cancer
Japan
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Anthracyclines
Prospective Studies
030212 general & internal medicine
Triple-negative breast cancer
Aged
Epirubicin
Dose-Response Relationship
Drug
business.industry
General Medicine
Middle Aged
Prognosis
medicine.disease
Survival Analysis
Regimen
Treatment Outcome
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
Surgery
Fluorouracil
business
medicine.drug
Zdroj: The Breast. 47:1-9
ISSN: 0960-9776
Popis: Background It is important to determine whether anthracycline-containing regimens or taxane-containing regimens are more effective in individual patients. The present study compared the efficacy of six cycles of docetaxel and cyclophosphamide (TC6) with that of three cycles of 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel (FEC-D) in Japanese patients with hormone receptor (HR)-negative breast cancer (BC) to identify subtypes requiring anthracycline treatment. Methods The study included 103 patients with operable HR-negative BC. Of these patients 53 received FEC-D and 50 received TC6. The primary endpoint was pathological complete response (pCR). The secondary endpoints were safety, breast-conserving surgery, disease-free survival (DFS) and overall survival (OS). The predictive factors for each regimen were evaluated. Results Of the 103 patients, 97 completed the study (FEC-D, 50 patients; TC6, 47 patients). The pCR rate was higher with FEC-D (36%) than with TC6 (25.5%); however, the difference was not significant (P = 0.265). TC6 was safer than FEC-D, as the adverse events with docetaxel in the FEC-D regimen were similar to those with the TC6 regimen. Among patients with basal BC, the pCR rate was significantly higher with FEC-D (42.9%) than with TC6 (13.6%; P = 0.033). Among patients with triple-negative breast cancer (TNBC), the DFS and OS were significantly better with FEC-D than with TC6 (P = 0.016 and P = 0.034, respectively). Conclusion TC6 was not as effective as FEC-D for treating HR-negative BC, as TC6 was not sufficient to treat TNBC, particularly the basal subtype. Our findings suggest that anthracyclines are better treatment options than taxanes for basal BC.
Databáze: OpenAIRE
Externí odkaz: